3,382 reports of this reaction
2.7% of all OXALIPLATIN reports
#8 most reported adverse reaction
THROMBOCYTOPENIA is the #8 most commonly reported adverse reaction for OXALIPLATIN, manufactured by Accord Healthcare Inc.. There are 3,382 FDA adverse event reports linking OXALIPLATIN to THROMBOCYTOPENIA. This represents approximately 2.7% of all 127,128 adverse event reports for this drug.
OXALIPLATIN has an overall safety score of 92 out of 100. Patients taking OXALIPLATIN who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for OXALIPLATIN, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for OXALIPLATIN:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 3,382 FDA reports for OXALIPLATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 2.7% of all adverse event reports for OXALIPLATIN, making it a notable side effect.
If you experience thrombocytopenia while taking OXALIPLATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.